Mga Batayang Estadistika
| CIK | 1659323 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Iterum Therapeutics plc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 20, 2025 |
FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 20, 2025 |
EXHIBIT 99.1 Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO – August 20, 2025 — Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and |
|
| August 5, 2025 |
EXHIBIT 99.1 Iterum Therapeutics Reports Second Quarter 2025 Financial Results - Launch of ORLYNVAHTM Expected August 2025— -Cash Runway into 2026- -Company to host conference call today at 8:30amET- DUBLIN, Ireland and CHICAGO, August 5, 2025 - Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug r |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 5, 2025 |
EXECUTION COPY Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| August 5, 2025 |
Exhibit 10.2 AMENDED AND RESTATED PROMISSORY NOTE $20,000,000 Dated: October 28, 2024 (as amended on May 12, 2025) This Amended and Restated Promissory Note due October 25, 2029 (this “A&R Note”) was originally issued as a Promissory Note due October 25, 2026 (the “Original Note”) on October 28, 2024 (the “Original Issue Date”) pursuant to Section 5.4.1 of the License Agreement, dated as of Novemb |
|
| August 5, 2025 |
3. Fair Value of Financial Assets and Liabilities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 5, 2025 |
Letter Agreement, dated May 13, 2025, by and between Iterum Therapeutics US Limited and Pfizer Inc. Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 11, 2025 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 19, 2025 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Announces Extension of Term of Promissory Note DUBLIN, Ireland and CHICAGO, May 19, 2025 - Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today report |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2025 |
3. Fair Value of Financial Assets and Liabilities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 13, 2025 |
EXHIBIT 99.1 Iterum Therapeutics Reports First Quarter 2025 Financial Results -Preparing for Potential Launch of ORLYNVAHTM by Q4 2025— -Extended Cash Runway into 2026- -Company to host conference call today at 8:30amET- DUBLIN, Ireland and CHICAGO, May 13, 2025 - Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections cau |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 30, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 28, 2025, between Iterum Therapeutics plc, an Irish incorporated public limited company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to th |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 28, 2025 ITERUM THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 001-38503 Not applicable (State or other jurisdiction of incorporation) (Commissio |
|
| April 30, 2025 |
Exhibit 4.1 PREFUNDED ORDINARY SHARE PURCHASE WARRANT ITERUM THERAPEUTICS PLC Warrant Shares: Initial Exercise Date: April , 2025 THIS PREFUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| April 30, 2025 |
Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares Exhibit 99.1 Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares DUBLIN, Ireland and CHICAGO, April 29, 2025 — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it ha |
|
| April 30, 2025 |
3,040,000 Ordinary Shares Pre-funded Warrants to Purchase 2,515,556 Ordinary Shares 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 14, 2025 |
February 14, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 7, 2025 |
EXHIBIT 10.22 Dated December 5, 2024 ITERUM THERAPEUTICS INTERNATIONAL LIMITED -and- MICHAEL DUNNE AMENDMENT TO CONTRACT FOR SERVICES THIS AMENDMENT to a CONTRACT FOR SERVICES is made and entered into on December 5, 2024, by and between: (1) Iterum Therapeutics International Limited whose registered office is at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24, Ireland (the Company); |
|
| February 7, 2025 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results -ORLYNVAHTM Approved by FDA in Q4 2024— -Extended Cash Runway- -Company to host conference call today at 8:30amET- DUBLIN, Ireland and CHICAGO, February 7, 2025 - Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat i |
|
| February 7, 2025 |
Exhibit 4.20 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Iterum Therapeutics plc (“we”, “us” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Ordinary Shares, $0.01 par value per share. DESCRIPTION OF SHARE CAPITAL The followi |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38503 Iterum Therapeu |
|
| February 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Iterum Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Fees to Be Paid Debt Debt Securities (1) (1) (1) (1) (1) (1) — — — — Fees to Be Paid Equity Ordinary Shares, nominal value $0. |
|
| February 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 07, 2025 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 7, 2025 |
As filed with the Securities and Exchange Commission on February 7, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on February 7, 2025 Registration No. |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 10, 2024 |
Up to $25,000,000 Ordinary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267795 PROSPECTUS SUPPLEMENT (To Prospectus dated October 17, 2022) Up to $25,000,000 Ordinary Shares We previously entered into an at the market offering agreement, dated as of October 7, 2022, or the sales agreement, with H.C. Wainwright & Co., LLC, or the Sales Agent or Wainwright, relating to the sale of our ordinary |
|
| November 21, 2024 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Regains Full Nasdaq Compliance -Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market- DUBLIN, Ireland and CHICAGO, November 21, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2024 |
ITRM / Iterum Therapeutics plc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
EXHIBIT 10.1 Dated August 9, 2024 ITERUM THERAPEUTICS INTERNATIONAL LIMITED -and- MICHAEL DUNNE AMENDMENT TO CONTRACT FOR SERVICES THIS AMENDMENT to a CONTRACT FOR SERVICES is made and entered into on August 9, 2024, by and between: (1) Iterum Therapeutics International Limited whose registered office is at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24, Ireland (the Company); and |
|
| November 14, 2024 |
SC 13G/A 1 p24-3181sc13ga.htm ITERUM THERAPEUTICS PLC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Iterum Therapeutics plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G6333L200 (a) (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat |
|
| November 14, 2024 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Third Quarter 2024 Financial Results - ORLYNVAHTM Approved by FDA on October 25, 2024— -Company to Host Conference Call Today at 8:30 a.m. EDT- DUBLIN, Ireland and CHICAGO, November 14, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections ca |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 1, 2024 |
Promissory Note dated October 28, 2024 from Iterum Therapeutics International Limited to Pfizer Inc. EXHIBIT 10.1 PROMISSORY NOTE $20,000,000 Dated: October 28, 2024 FOR VALUE RECEIVED, the undersigned Iterum Therapeutics International Limited, a company organized and existing under the laws of Ireland having its registered office address at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2 (together with its permitted successors and assigns, "Maker"), hereby promises to pay to the order of Pf |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 30, 2024 |
Up to $1,173,214 Ordinary Shares 424B5 PROSPECTUS SUPPLEMENT (To Prospectus dated October 17, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| October 28, 2024 |
Up to $4,011,463 Ordinary Shares 424B5 PROSPECTUS SUPPLEMENT (To Prospectus dated October 17, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 25, 2024 |
EXHIBIT 99.1 Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades -Company to Host Conference Call on Monday, October 28th at 8:30 a.m. EDT- DUBLIN, Ireland and CHICAGO, October 25, |
|
| October 15, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 09, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 11, 2024 |
Up to $1,713,895 Ordinary Shares PROSPECTUS SUPPLEMENT (To Prospectus dated October 17, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| October 8, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 08, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 4, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 01, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 14, 2024 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Second Quarter 2024 Financial Results - FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— -Cash Runway into 2025, including through PDUFA Action Date- -Company to Host Conference Call Today at 8:30 a.m. EDT- DUBLIN, Ireland and CHICAGO, August 14, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM), |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| August 14, 2024 |
EXHIBIT 10.1 Dated May 29, 2024 ITERUM THERAPEUTICS INTERNATIONAL LIMITED -and- DR. SAILAJA PUTTAGUNTA CONTRACT FOR SERVICES 1 THIS AGREEMENT is dated May 29, 2024 and made between: (1) Iterum Therapeutics International Limited whose registered office is at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24, Ireland (the Company) and (2) Dr. Sailaja Puttagunta with an address at 39 Bue |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 POS AM 1 d787428dposam.htm POS AM As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333-280045 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ITERUM THERAPEUTICS PLC (Exact name of registrant as specified in its charter) Ireland 2834 98-1 |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 6, 2024 |
EXHIBIT 99.1 August 6, 2024 Iterum Therapeutics Announces Expiration and Results of Rights Offering DUBLIN and CHICAGO, August 6, 2024 (GLOBE NEWSWIRE) – Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospi |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 22, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 22, 2024 |
Iterum Therapeutics Commences Rights Offering EXHIBIT 99.1 Iterum Therapeutics Commences Rights Offering DUBLIN, Ireland and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) – Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced tha |
|
| July 19, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-280045 PROSPECTUS ITERUM THERAPEUTICS PLC 17,007,601 Non-Transferable Subscription Rights to purchase 8,503,800 Units, at a Subscription Price of $1.21 per whole Unit, each whole Unit consisting of one Ordinary Share, a 1-Year Warrant to purchase 0.50 Ordinary Shares and a 5-Year Warrant to purchase one Ordinary Shar |
|
| July 17, 2024 |
July 17, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Tim Buchmiller Re: Iterum Therapeutics plc Registration Statement on Form S-1 File No. |
|
| July 17, 2024 |
Exhibit 4.19 + Computershare Trust Company, N.A. 150 Royall Street Suite V Canton, Massachusetts 02021 Information Agent: Georgeson LLC Banks, brokers and shareholders call toll-free: 866-413-5899 ITERUM THERAPEUTICS PLC MR A SAMPLE ITERUM THERAPEUTICS PLC SUBSCRIPTION RIGHTS CERTIFICATE THIS SUBSCRIPTION RIGHTS OFFERING (THE “RIGHTS OFFERING”) EXPIRES AT 5:00 P.M., EASTERN TIME, ON AUGUST 6, 2024 |
|
| July 17, 2024 |
Form of Letter to Clients of Brokers, Dealers, Custodian Banks and Other Nominees Exhibit 99.4 FORM OF LETTER TO CLIENTS OF BROKERS, DEALERS, CUSTODIAN BANKS AND OTHER NOMINEES ITERUM THERAPEUTICS PLC 17,007,601 Non-Transferable Subscription Rights to purchase 8,503,800 Units, at a Subscription Price of $1.21 per whole Unit, each whole Unit consisting of one Ordinary Share, a 1-Year Warrant to purchase 0.50 Ordinary Shares and a 5-Year Warrant to purchase one Ordinary Share Dis |
|
| July 17, 2024 |
Form of Letter to Brokers, Dealers, Custodian Banks and Other Nominees Exhibit 99.3 FORM OF LETTER TO BROKERS, DEALERS, CUSTODIAN BANKS AND OTHER NOMINEES ITERUM THERAPEUTICS PLC 17,007,601 Non-Transferable Subscription Rights to purchase 8,503,800 Units, at a Subscription Price of $1.21 per whole Unit, each whole Unit consisting of one Ordinary Share, a 1-Year Warrant to purchase 0.50 Ordinary Shares and a 5-Year Warrant to purchase one Ordinary Share Distributed to |
|
| July 17, 2024 |
Exhibit 4.17 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Agreement”) between Iterum Therapeutics plc, a public limited company incorporated under the laws of Ireland (registered number 563531) (the “Company”), Computershare Inc., a Delaware corporation (“Computershare”) and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (“Trust Company”, and to |
|
| July 17, 2024 |
Form of 1-Year Warrant to Subscribe for Ordinary Shares Exhibit 4.15 ITERUM THERAPEUTICS PLC 1-Year Warrant to Purchase Ordinary Shares Warrant Shares: Initial Exercise Date: , 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value of $0.0001 received by Iterum Therapeutics plc, an Irish incorporated public limited company, (the “Company”), or its assigns (the “Holder”), is entitled, upon the terms and subject to the li |
|
| July 17, 2024 |
Form of Notice of Important Tax Information Exhibit 99.5 FORM OF NOTICE OF IMPORTANT TAX INFORMATION ITERUM THERAPEUTICS PLC This notice is provided in connection with the prospectus of Iterum Therapeutics plc, an Irish public limited company (the “Company”) dated July , 2024. Under the U.S. federal income tax laws, distributions (including constructive distributions) that may be made by the Company in respect of the Company’s ordinary shar |
|
| July 17, 2024 |
Form of Dealer-Manager Agreement, by and between Iterum Therapeutics plc and Maxim Group LLC Exhibit 1.1 ITERUM THERAPEUTICS PLC. DEALER-MANAGER AGREEMENT July , 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 As Dealer-Manager Ladies and Gentlemen: The following will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by Iterum Therapeutics PLC., an Irish public limited company (the “Company”), pursuant to which th |
|
| July 17, 2024 |
Instructions as to Use of Rights Certificates Exhibit 99.1 INSTRUCTIONS AS TO USE OF ITERUM THERAPEUTIC PLC SUBSCRIPTION RIGHTS CERTIFICATES Please consult Georgeson LLC (the “Information Agent”), the information agent for the Rights Offering, or your bank or broker as to any questions The following instructions relate to a subscription rights offering (the “Rights Offering”) by Iterum Therapeutics plc, an Irish public limited company (the “C |
|
| July 17, 2024 |
Exhibit 4.18 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Agreement”) between Iterum Therapeutics plc, a public limited company incorporated under the laws of Ireland (registered number 563531) (the “Company”), Computershare Inc., a Delaware corporation (“Computershare”) and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (“Trust Company”, and to |
|
| July 17, 2024 |
As filed with the Securities and Exchange Commission on July 17, 2024 Table of Contents As filed with the Securities and Exchange Commission on July 17, 2024 Registration No. |
|
| July 17, 2024 |
Form of 5-Year Warrant to Subscribe for Ordinary Shares Exhibit 4.16 ITERUM THERAPEUTICS PLC 5-Year Warrant to Purchase Ordinary Shares Warrant Shares: Initial Exercise Date: , 2024 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value of $0.0001 received by Iterum Therapeutics plc, an Irish incorporated public limited company, (the “Company”), or its assigns (the “Holder”), is entitled, upon the terms and subject to the li |
|
| July 17, 2024 |
Form of Letter to Shareholders and Holders of Eligible Warrants Who are Record Holders Exhibit 99.2 FORM OF LETTER TO SHAREHOLDERS AND HOLDER OF ELIGIBLE WARRANTS WHO ARE RECORD HOLDERS ITERUM THERAPEUTICS PLC 17,007,601 Non-Transferable Subscription Rights to purchase 8,503,800 Units, at a Subscription Price of $1.21 per whole Unit, each whole Unit consisting of one Ordinary Share, a 1-Year Warrant to purchase 0.50 Ordinary Shares and a 5-Year Warrant to purchase one Ordinary Share |
|
| June 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Iterum Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registratio |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 26, 2024 S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 26, 2024 Registration No. |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 21, 2024 |
EXHIBIT 99.1 Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections -Proposed Date for Advisory Committee meeting is September 9, 2024- DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused |
|
| June 7, 2024 |
As filed with the Securities and Exchange Commission on June 7, 2024 S-1 Table of Contents As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. |
|
| June 7, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Iterum Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount o |
|
| May 31, 2024 |
EXHIBIT 99.1 Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections -Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024- DUBLIN, Ireland and CHICAGO, May 31, 2024 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2024 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports First Quarter 2024 Financial Results -NDA Resubmitted; FDA Action Expected in Early Q4 24— -Cash Runway into 2025, including through Potential FDA Approval- -Company to Host Conference Call Today at 8:30 a.m. EDT- DUBLIN, Ireland and CHICAGO, May 13, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum) a clinical-stage pharmaceutica |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 29, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 29, 2024 |
Exhibit 99.1 Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem -First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved- -Potential Approval Early Q4 2024- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceut |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 5, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 03, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 29, 2024 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results -Resubmission of NDA On Track for Early Q2 24— -Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24- -Company to host conference call today at 8:30amET- DUBLIN, Ireland and CHICAGO, March 28, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage ph |
|
| March 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38503 Iterum Therapeu |
|
| March 28, 2024 |
Insider Trading and Trading Window Policy EXHIBIT 19.1 INSIDER TRADING AND TRADING WINDOW POLICY APPROVED BY THE BOARD OF DIRECTORS MARCH 14, 2018 I. INTRODUCTION This policy determines acceptable transactions in the securities of Iterum Therapeutics plc (the “Company”) by our employees, directors and consultants (and the employees and consultants of any of the Company’s subsidiaries). During the course of your employment, directorship or |
|
| March 28, 2024 |
Policy for the Recovery of Erroneously Awarded Compensation, effective October 2, 2023 EXHIBIT 97.1 Policy for the Recovery of Erroneously Awarded Compensation A. OVERVIEW This Policy for the Recovery of Erroneously Awarded Compensation (this “Policy”) is adopted by Iterum Therapeutics plc (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”). This Policy is effective as of October 2, 2023 (the “Effective Date”). B. DEFINITIONS (a) “Accounting Restatement” means |
|
| March 28, 2024 |
EXHIBIT 10.20 Dated December 27, 2023 ITERUM THERAPEUTICS INTERNATIONAL LIMITED -and- MICHAEL DUNNE AMENDMENT TO CONTRACT FOR SERVICES THIS AMENDMENT to a CONTRACT FOR SERVICES is made and entered into on December 27, 2023, by and between: (1) Iterum Therapeutics International Limited whose registered office is at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24, Ireland (the Company |
|
| March 28, 2024 |
Description of Registrant's Securities Exhibit 4.15 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Iterum Therapeutics plc (“we”, “us” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Ordinary Shares, $0.01 par value per share. DESCRIPTION OF SHARE CAPITAL The followi |
|
| March 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 6, 2024 |
EXHIBIT 99.1 Iterum Therapeutics Provides Business Update Resubmission of NDA is On Track for First Half of Q2 24 Extended Cash Runway into 2025 DUBLIN, Ireland and CHICAGO, March 6, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in co |
|
| January 31, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0546exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| January 31, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Iterum Therapeutics plc (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G6333L200 (a) (CUSIP Number) January 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 30, 2024 |
REASSURE Phase 3 Topline Data Conference Call January 30, 2024 EXHIBIT 99.2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, the Company’s ability to address the deficienci |
|
| January 30, 2024 |
Exhibit 99.1 Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority to Augmentin®; Demonstrated Statistical Superiority Re-submission of NDA to FDA Expected in Q2 2024 Potential to be First Oral Penem Approved in the U.S. Management to |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 4, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 4, 2023 |
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule EXHIBIT 99.1 Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule DUBLIN, Ireland and CHICAGO, December 4, 2023 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settin |
|
| November 14, 2023 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Third Quarter 2023 Financial Results - Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – -Resubmission of NDA for uUTI Expected in Q2 2024- DUBLIN, Ireland and CHICAGO, November 14, 2023 - Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation or |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 24, 2023 |
EXHIBIT 99.1 Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections - Topline Data Expected in Early Q1 2024 – - NDA Resubmission Expected in Q2 2024 – DUBLIN, Ireland and CHICAGO, October 24, 2023 - Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on d |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 11, 2023 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Second Quarter 2023 Financial Results -Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 - -Cash Runway into Q3 2024- DUBLIN, Ireland and CHICAGO, August 11, 2023 - Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiot |
|
| August 11, 2023 |
EXHIBIT 10.1 Dated June 15, 2023 ITERUM THERAPEUTICS INTERNATIONAL LIMITED -and- MICHAEL DUNNE AMENDMENT TO CONTRACT FOR SERVICES THIS AMENDMENT to a CONTRACT FOR SERVICES is made and entered into on June 15, 2023, by and between: (1) Iterum Therapeutics International Limited whose registered office is at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24, Ireland (the Company); and (2 |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 25, 2023 |
VIA EDGAR May 25, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2023 |
EX-99.1 2 itrm-ex991.htm EX-99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports First Quarter 2023 Financial Results -Registration Trial for uUTI Ongoing and On Track- -Cash Runway until Mid-2024- DUBLIN, Ireland and CHICAGO, May 12, 2023 - Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV anti |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 03, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 4, 2023 |
Amended and Restated Constitution of Iterum Therapeutics plc EXHIBIT 3.1 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY (as amended by all resolutions up to and including May 03, 2023) COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Iterum Therapeutics public limited company. 2. The Com |
|
| April 13, 2023 |
DEFA14A 1 defa14a-additionalmat.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl |
|
| March 16, 2023 |
COURTESY COPY OF DEF_PROXY_AGM_2023_15_03 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. |
|
| March 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 16, 2023 |
Exhibit 10.18 Dated December 31, 2022 ITERUM THERAPEUTICS INTERNATIONAL LIMITED -and- MICHAEL DUNNE AMENDMENT TO CONTRACT FOR SERVICES THIS AMENDMENT to a CONTRACT FOR SERVICES is made and entered into on December 31, 2022 by and between: (1) Iterum Therapeutics International Limited whose registered office is at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, D02 YW24, Ireland (the Company) |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38503 Iterum Therapeu |
|
| March 16, 2023 |
DEFA14A 1 defa14a-noticeandacc.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 16, 2023 |
Description of Registrant's Securities Exhibit 4.15 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Iterum Therapeutics plc (“we”, “us” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Ordinary Shares, $0.01 par value per share. DESCRIPTION OF SHARE CAPITAL The followi |
|
| March 16, 2023 |
EX-99 2 itrm-ex991.htm EX-99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results -Registration Trial for uUTI Ongoing and On Track- -Cash Runway until Mid-2024- -Company to host conference call today at 8:30amET- DUBLIN, Ireland and CHICAGO, March 16, 2023 - Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical comp |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 15, 2022 |
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem Exhibit 99.1 Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem DUBLIN, Ireland and CHICAGO, December 15, 2022 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathog |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2022 |
Iterum Therapeutics plc 2021 Inducement Equity Incentive Plan, as amended EXHIBIT 10.3 ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1. GENERAL. (a) Eligible Award Recipients. Awards under the 2021 Inducement Equity Incentive Plan (the ?Plan?) may only be granted to persons who (a) were not previously an Employee or Director of the Company or an Affiliate or (b) are commencing employment with the Company or an Affiliate following a bon |
|
| November 10, 2022 |
2015 Equity Incentive Plan, as amended EXHIBIT 10.1 ITERUM THERAPEUTICS LIMITED 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: November 18, 2015 APPROVED BY THE SHAREHOLDERS: November 18, 2015 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: December 7, 2016 AMENDED BY THE BOARD OF DIRECTORS: May 17, 2017 AMENDED BY THE SHAREHOLDERS: May 17, 2017 TERMINATION DATE: November 17, 2025 1. GENERAL. (a) Eligible Stock Award Rec |
|
| November 10, 2022 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Third Quarter 2022 Financial Results -Patient Enrollment in Registration Trial for uUTI Underway- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, November 10, 2022 - Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infe |
|
| November 10, 2022 |
Amended and Restated 2018 Equity Incentive Plan, as amended EXHIBIT 10.2 ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Relationship to Prior Plan. (i) This Plan is intended as the successor to the Iterum Therapeutics Public Limited Company (formerly Iterum Therapeutics Limited) 2015 Equity Incentive Plan (the ?Prior Plan?) with respect to grants to Employees. From and after 12:01 a.m. Central tim |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| October 20, 2022 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections - NDA resubmission expected in Second Half of 2024, if successful- -Oral sulopenem, if approved, could be the first antibiotic approved for uncomplicated urinary tract infections in over 25 years- DUBLIN and CHICAGO, October 20, 2 |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 13, 2022 |
ITERUM THERAPEUTICS PLC Fitzwilliam Court, 1st Floor Leeson Close, Dublin 2 ITERUM THERAPEUTICS PLC Fitzwilliam Court, 1st Floor Leeson Close, Dublin 2 Ireland October 13, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 7, 2022 |
Form of Subordinated Indenture Exhibit 4.3 ITERUM THERAPEUTICS PLC and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b |
|
| October 7, 2022 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT October 7, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Iterum Therapeutics plc, a corporation organized under the laws of Ireland (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Manager?) as follows: 1.Definitions. The terms that follow, when used in this |
|
| October 7, 2022 |
Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| October 7, 2022 |
Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| October 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Iterum Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Fees to Be Paid Debt Debt Securities (1) (1) (1) (1) (1) (1) - - - - Fees to Be Paid Equity Ordinary Shares, nominal value $0. |
|
| October 7, 2022 |
As filed with the Securities and Exchange Commission on October 7, 2022 As filed with the Securities and Exchange Commission on October 7, 2022 Registration No. |
|
| October 7, 2022 |
Exhibit 4.2 ITERUM THERAPEUTICS PLC and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 1 This Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311( |
|
| September 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 19, 2022 |
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem Exhibit 99.1 Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem DUBLIN, Ireland and CHICAGO, September 19, 2022 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the ?Company? or ?Iterum?), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant patho |
|
| August 19, 2022 |
Amended and Restated Constitution of Iterum Therapeutics plc EXHIBIT 3.1 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY (as amended by all resolutions up to and including 15 June 2022) COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY 1. The name of the Company is Iterum Therapeutics public limited company. 2. The Com |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 12, 2022 |
EXHIBIT 10.1 Dated May 25, 2022 ITERUM THERAPEUTICS INTERNATIONAL LIMITED -and- MICHAEL DUNNE CONTRACT FOR SERVICES THIS AGREEMENT is dated May 25 , 2022 and made between: (1) Iterum Therapeutics International Limited whose registered office is at Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, DO2 YW24, Ireland (the Company); and (2) Michael Dunne of 30 Cromwell Place, Old Saybrook, CT, 064 |
|
| August 12, 2022 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Second Quarter 2022 Financial Results -Enrollment in Registration Trial for uUTI to Begin Q4 2022- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, August 12, 2022 - Iterum Therapeutics plc (Nasdaq: ITRM) (?Iterum?), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infec |
|
| August 12, 2022 |
EXHIBIT 10.2 SHARE OPTION CANCELLATION AGREEMENT This SHARE OPTION CANCELLATION AGREEMENT (the ?Agreement?) is made and entered into as of July 7, 2022 (the ?Effective Date?), by and between Corey N. Fishman (the ?Optionee?) and Iterum Therapeutics plc, an Irish incorporated public limited company (the ?Company?). WHEREAS, the Company has previously granted to the Optionee share options (the ?Opti |
|
| August 12, 2022 |
EXHIBIT 10.3 SHARE OPTION CANCELLATION AGREEMENT This SHARE OPTION CANCELLATION AGREEMENT (the ?Agreement?) is made and entered into as of July 7, 2022 (the ?Effective Date?), by and between Judith M. Matthews (the ?Optionee?) and Iterum Therapeutics plc, an Irish incorporated public limited company (the ?Company?). WHEREAS, the Company has previously granted to the Optionee share options (the ?Op |
|
| August 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 11, 2022 |
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA -SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections- -Clinical Trial Expected to Begin Enrollment in Q4 2022- DUBLIN, Ireland and CHICAGO; July 11, 2022 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the ?Company?), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced today that it has reached an agreement with the U. |
|
| July 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 8, 2022 |
SHARE OPTION CANCELLATION AGREEMENT EXHIBIT 99.1 SHARE OPTION CANCELLATION AGREEMENT This SHARE OPTION CANCELLATION AGREEMENT (the ?Agreement?) is made and entered into as of July 7, 2022 (the ?Effective Date?), by and between [] (the ?Optionee?) and Iterum Therapeutics plc, an Irish incorporated public limited company (the ?Company?). WHEREAS, the Company has previously granted to the Optionee share options (the ?Options?) to purch |
|
| July 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 07, 2022 Iterum Therapeutics plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-38503 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS Emp |
|
| May 13, 2022 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports First Quarter 2022 Financial Results -General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 - Iterum Therapeutics plc (Nasdaq: ITRM) (?Iterum?), a clinical-stage pharmaceutical company focused on developing next generation oral and IV |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 28, 2022 |
EXHIBIT 10.19 ITERUM THERAPEUTICS US LIMITED October 25, 2021 Sailaja Puttagunta 39 Buell Hill Road Killingworth, Ct. 06419 Re:Employment Terms Dear Sailaja: On behalf of Iterum Therapeutics US Limited (the ?Company?), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (the ?Agreement?). As discussed, the terms of this Agreement govern with re |
|
| March 28, 2022 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results -Registration Trial for uUTI Planned in Second Half of 2022- -Cash Runway into 2024? -Company to host conference call today at 8:30amET- DUBLIN, Ireland and CHICAGO, March 28, 2022 - Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS E |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38503 Iterum Therapeu |
|
| December 9, 2021 |
As filed with the Securities and Exchange Commission on December 9, 2021 As filed with the Securities and Exchange Commission on December 9, 2021 Registration No. |
|
| December 9, 2021 |
EXHIBIT 99.2 ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY Nonstatutory Share OPTION GRANT NOTICE (2021 Inducement EQUITY INCENTIVE PLAN) Iterum Therapeutics Public Limited Company, a public limited company organized under the laws of Ireland (the ?Company?), pursuant to its 2021 Inducement Equity Incentive Plan (the ?Plan?), hereby grants to Participant an option to purchase the number of Ordinary S |
|
| December 9, 2021 |
Form of Restricted Share Unit Award Agreement under the 2021 Inducement Equity Incentive Plan EXHIBIT 99.4 Iterum Therapeutics Public Limited Company Restricted Share Unit Grant Notice (2021 Inducement Equity Incentive Plan) Iterum Therapeutics Public Limited Company, a public limited company organized under the laws of Ireland (the ?Company?), pursuant to its 2021 Inducement Equity Incentive Plan (the Plan), hereby awards to Participant the number of restricted share units (the ?Restricte |
|
| December 9, 2021 |
Iterum Therapeutics plc 2021 Inducement Equity Incentive Plan, as amended EXHIBIT 99.1 ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1.GENERAL. (a)Eligible Award Recipients. Awards under the 2021 Inducement Equity Incentive Plan (the ?Plan?) may only be granted to persons who (a) were not previously an Employee or Director of the Company or an Affiliate or (b) are commencing employment with the Company or an Affiliate following a bona |
|
| December 9, 2021 |
EXHIBIT 99.3 Iterum THERAPEUTICS PUBLIC LIMITED COMPANY Nonstatutory Share OPTION GRANT NOTICE (2021 Inducement EQUITY INCENTIVE PLAN) Iterum Therapeutics Public Limited Company, a public limited company organized under the laws of Ireland (the ?Company?), pursuant to its 2021 Inducement Equity Incentive Plan (the ?Plan?), hereby grants to Participant an option to purchase the number of Ordinary S |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IR |
|
| November 12, 2021 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update -Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem - -Cash Runway into 2024- -Iterum to host conference call today at 8:30am ET- DUBLIN, Ireland and CHICAGO, November 12, 2021 - Iterum Therap |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IR |
|
| August 13, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update -Type A meeting with FDA expected late Q3 to define pathway to potential approval for Oral Sulopenem following July?s Complete Response Letter- -Cash Runway into Second Half of 2023- -Company to host conference call today at 8:30am ET- DUBLIN, Ireland and CHICAGO, Augus |
|
| August 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| July 26, 2021 |
EXHIBIT 99.1 Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem DUBLIN, Ireland and CHICAGO; July 26, 2021 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the ?Company?), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant path |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| July 2, 2021 |
Iterum Therapeutics Provides Regulatory Update EXHIBIT 99.1 Iterum Therapeutics Provides Regulatory Update DUBLIN, Ireland and CHICAGO; July 01, 2021 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the ?Company?), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced th |
|
| July 2, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS Emp |
|
| June 23, 2021 |
ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN EX-99.1 2 itrm-ex9916.htm EX-99.1 EXHIBIT 99.1 ITERUM THERAPEUTICS PUBLIC LIMITED COMPANY AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN 1.GENERAL. (a) Relationship to Prior Plan. (i) This Plan is intended as the successor to the Iterum Therapeutics Public Limited Company (formerly Iterum Therapeutics Limited) 2015 Equity Incentive Plan (the “Prior Plan”) with respect to grants to Employees. From |
|
| June 23, 2021 |
As filed with the Securities and Exchange Commission on June 23, 2021 As filed with the Securities and Exchange Commission on June 23, 2021 Registration No. |
|
| June 23, 2021 |
8-K 1 itrm-8k20210623.htm 8-KAGM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| May 27, 2021 |
Iterum Therapeutics Provides Update on NDA Review EXHIBIT 99.1 Iterum Therapeutics Provides Update on NDA Review DUBLIN, Ireland and CHICAGO; May 27, 2021 (GLOBE NEWSWIRE) - Iterum Therapeutics plc (Nasdaq: ITRM) (the ?Company?), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced |
|
| May 27, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS Emp |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38503 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 98-1283148 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 14, 2021 |
EXHIBIT 10.2 Mr. Michael Dunne 30 Cromwell Place, Old Saybrook, CT 06475 February 17, 2021 RE: Options and Restricted Share Units granted pursuant to the Iterum Therapeutics Public Limited Company 2018 Equity Incentive Plan (as amended and restated) (the 2018 Plan) Dear Mike, We refer to your recent resignation as Chief Scientific Offer and employee of Iterum Therapeutics US Limited (ITUS), effect |
|
| May 14, 2021 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports First Quarter 2021 Financial Results FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021 Cash Runway into First Half of 2023 Company to host conference call today at 8:30am ET DUBLIN, Ireland and CHICAGO, May 14, 2021 - Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-s |
|
| May 14, 2021 |
EXHIBIT 10.1 Dated February 21, 2021 ITERUM THERAPEUTICS INTERNATIONAL LIMITED -and- MICHAEL DUNNE CONTRACT FOR SERVICES 1 THIS AGREEMENT is dated February 21, 2021 and made between: (1) Iterum Therapeutics International Limited whose registered office is at Block 2 Floor 3 Harcourt Centre, Harcourt Street, Dublin 2, Ireland (the Company); and (2) Michael Dunne of 30 Cromwell Place, Old Saybrook, |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS Emp |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 08, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS E |
|
| March 16, 2021 |
ITERUM THERAPEUTICS APPOINTS BETH P. HECHT TO BOARD OF DIRECTORS Patrick Heron to leave the Board EXHIBIT 99.1 ITERUM THERAPEUTICS APPOINTS BETH P. HECHT TO BOARD OF DIRECTORS Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, IL March 16, 2021 – Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both c |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS E |
|
| March 16, 2021 |
Amended and Restated Non-Employee Director Compensation Policy EXHIBIT 10.1 ITERUM THERAPEUTICS PLC Amended and Restated NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Members of the board of directors (the ?Board?) of Iterum Therapeutics plc (the ?Company?) shall be eligible to receive the cash and equity compensation for their service on the Board and any committee of the Board (a ?Committee?) as set forth in this Non-Employee Director Compensation Policy (this |
|
| March 12, 2021 |
Subsidiary Guarantors and Subsidiary Issuers Exhibit 22.1 Subsidiary Issuers and Subsidiary Guarantors of Guaranteed Securities Guaranteed Security Subsidiary Issuer Co-Guarantors 6.500% Exchangeable Senior Subordinated Notes due 2025 Iterum Therapeutics Bermuda Limited ?Iterum Therapeutics International Limited (subsidiary guarantor) ?Iterum Therapeutics US Limited (subsidiary guarantor) ?Iterum Therapeutics US Holding Limited (subsidiary g |
|
| March 12, 2021 |
Amended and Restated Certificate of Incorporation of Iterum Therapeutics US Limited Exhibit 3.5 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ITERUM THERAPEUTICS US LIMITED Judith M. Matthews hereby certifies that: ONE: The date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was October 21, 2015. TWO: She is the duly elected and acting President of Iterum Therapeutics US Limited, a Delaware corpo |
|
| March 12, 2021 |
Certificate of Amendment of Certificate of Incorporation of Iterum Therapeutics US Holding Limited Exhibit 3.7 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ITERUM THERAPEUTICS US HOLDINGS LIMITED ITERUM THERAPEUTICS US HOLDINGS LIMITED, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), hereby certifies that: FIRST: The name of the Corporation is Iterum Therapeutics US Holdings Limited. SECOND: The |
|
| March 12, 2021 |
Description of Registrant's Securities Exhibit 4.15 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Iterum Therapeutics plc (?we?, ?us? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our Ordinary Shares, $0.01 par value per share. DESCRIPTION OF SHARE CAPITAL The followi |
|
| March 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IRS E |
|
| March 12, 2021 |
Exhibit 10.28 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 9, 2021, between Iterum Therapeutics plc, an Irish incorporated public limited company (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to |
|
| March 12, 2021 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results -NDA for Oral Sulopenem has PDUFA date of July 25, 2021- -Cash Runway into First Half of 2023— -Company to host conference call today at 8:30amET- DUBLIN, Ireland and CHICAGO, March 12, 2021 - Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on d |
|
| March 12, 2021 |
Bylaws of Iterum Therapeutics US Holding Limited Exhibit 3.8 BYLAWS OF ITERUM THERAPEUTICS US HOLDING LIMITED (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 251 Little Falls Drive, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors may from time to time determine or the business of the corporation |
|
| March 12, 2021 |
w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38503 Iterum Therap |
|
| March 12, 2021 |
Bylaws of Iterum Therapeutics US Limited Exhibit 3.6 BYLAWS OF ITERUM THERAPEUTICS US LIMITED (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors may from time to time determine or the business of the corporatio |
|
| March 12, 2021 |
Constitution of Iterum Therapeutics International Limited Exhibit 3.4 COMPANIES ACT 2014 PRIVATE COMPANY LIMITED BY SHARES CONSTITUTION OF ITERUM THERAPEUTICS INTERNATIONAL LIMITED (as amended by special resolution dated 13 June 2018) 1 COMPANIES ACT 2014 PRIVATE COMPANY LIMITED BY SHARES CONSTITUTION OF ITERUM THERAPEUTICS INTERNATIONAL LIMITED 1. Company Name: The name of the company is: ITERUM THERAPEUTICS INTERNATIONAL LIMITED. 2. Company Type: The c |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Iterum Therapeutics plc (Exact name of registrant as specified in its charter) Ireland 001-38503 98-1283148 (State or other jurisdiction (Commission File Number) (IR |
